Galectin Therapeutics Inc’s recently made public that its Director ELDRED KARY acquired Company’s shares for reported $2925.0 on Jul 21 ’25. In the deal valued at $2.92 per share,1,000 shares were bought. As a result of this transaction, ELDRED KARY now holds 64,682 shares worth roughly $0.18 million.
Then, FREEMAN KEVIN D bought 5,000 shares, generating $14,495 in total proceeds. Upon buying the shares at $2.90, the Director now owns 49,769 shares.
Before that, Shlevin Harold H. bought 6,500 shares. Galectin Therapeutics Inc shares valued at $7,540 were divested by the Director at a price of $1.16 per share. As a result of the transaction, Shlevin Harold H. now holds 15,206 shares, worth roughly $43489.159999999996.
A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in mid August has reiterated a ‘”a Buy”‘ rating for it. B. Riley FBR began covering GALT with “Buy” recommendation on February 13, 2019. H.C. Wainwright maintained its rating on December 07, 2017. It rated GALT as “a Buy”.
Price Performance Review of GALT
On Tuesday, Galectin Therapeutics Inc [NASDAQ:GALT] saw its stock jump 4.38% to $2.86. Over the last five days, the stock has gained 2.14%. Galectin Therapeutics Inc shares have risen nearly 13.94% since the year began. Nevertheless, the stocks have risen 121.71% over the past one year. While a 52-week high of $3.90 was reached on 06/20/25, a 52-week low of $0.73 was recorded on 01/14/25.
Levels Of Support And Resistance For GALT Stock
The 24-hour chart illustrates a support level at 2.63, which if violated will result in even more drops to 2.41. On the upside, there is a resistance level at 2.99. A further resistance level may holdings at 3.13.
How much short interest is there in Galectin Therapeutics Inc?
A steep rise in short interest was recorded in Galectin Therapeutics Inc stocks on 2025-06-30, dropping by -1.11 million shares to a total of 7.79 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-30 was 8.9 million shares. There was a decline of -14.29%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 28, 2017 when H.C. Wainwright resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $6.
